PreveCeutical Medical Inc (PRVCF)

[PickPen]

Yes it will. A lot going on behind the scenes.
I’m long on this one and very bullish.

[704 Hauser St]

Guess today should have been expected, albeit a little more harsh than anticipated. This will be an interesting week.

[PickPen]

We all know it’s coming soon.

[weathervane]

I wouldn't be surprised if we get an answer by the end of the month regarding the 29.5 million SIF funding. Another big surge when it happens.

[PickPen]

So much potential with this company.

[weathervane]

Mucous membranes are epithelial cells (like skin) so this sol-gel would presumably stick to surface skin cells as well, making it another form of infection prevention during surgery. Or protection against other things harmful to exposed skin. This just gets better and better.

[PickPen]

$EVFM has a drug in testing to prevent STD’s for women by blocking mucus membranes in the vagina. They also have a non steroidal birth control thats FDA approved that hasn’t made it to market yet.
Your right. The applications could be unlimited. Glad to see the filing of a patent for this application technology.

[weathervane]

I just thought of some other uses, like coating a mucous membrane during surgery to prevent infection, or protecting mucous membranes from other pathogens like toxic gas. Would it work to prevent STDs in women? Their vagina and cervix are covered with mucous membranes. These aren't very far-fetched speculations.

[PickPen]

Great point.

[weathervane]

Oh yeah, 1.00 is more than realistic. We are going to make some real money here for sure. What I would like to know is, just what percentage of the entire nasal cavity their sol-gel and applicator can reach, and what is different about their applicator. What percentage of the nasal cavity is covered by the sol-gel after two applications in a row, or three? Can 100% be reached after enough applications? It sticks to the mucosa for an entire week, if I remember right. If that is the case, it can prevent ANY virus from infecting people through the nose, including the flu or common cold. Does it work on peoples throats? What if it does? A mucous membrane is a mucous membrane. What if it sticks to a throat as well as a nasal cavity? Talk about huge medical news if it does.

[PickPen]

With steady price holding with high volume means accumulation I would think. So much in the future for us long’s. I can see this making it to at least a buck and prob more with positive news going forward.
Def a reason to be excited.

Bullish

[PickPen]

I’ll take a penny gain every day till Christmas.
They get this CBD nasal spray developed and it works we will be noticed through out the medical world.

[weathervane]

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

[weathervane]

More progress! Should be another high volume green day!

[PickPen]

Same here. Company is not known for pr after or to pump their stock. Their main focus is business development. I like that business model.

Bullish long term.

[JEB1958]

Been here for awhile. Quiet and like it.

[PickPen]

I agree. Stocktwits don’t post any pinks on their site. If this company gets to that level and makes it to stock twits and posts good news this will def move the needle up a bunch.

[weathervane]

There are lots of people on yahoo who know all about this co. and zero here on ihub. It's really weird.

[PickPen]

I agree. The nasal spray tech is big. I’m in for the long haul.

[weathervane]

Amazingly quiet board considering everything Preveceutical has going on. For some strange reason this doesn't seem to be on many radar screens. They make no bones about the fact they're interested in partnering with other companies, and that facility they are constructing in Australia sounds like it will be of some size. They've set themselves up to be a major (THE major?) player in Australia's cannabidiol market in addition to everything else. Their peptide patents and the medicine behind them are very promising.

[ZDSinvesting]

Big things on the way. Hold them shares right! Good luck!

[marktheinvestor]

Asterion Signs Exclusive Definitive Association Agreement for $400 Million Financing, Development and Construction

https://www.bloomberg.com/press-releases/2020-03-31/asterion-signs-exclusive-definitive-association-agreement-for-400-million-financing-development-and-construction

[marktheinvestor]

Saw a few interesting posts on Facebook investors Group.

"Yes our staff in the university is fully operational. As they work in a Pharma sterile environment. Our head office staff all work remotely from home and are still as efficient as ever. "

" We are working on that right now with another pharmaceutical company to partner with.
Money is always tight but we seem to manage. So a partnership in the next month or so will help "

"The Sol-Gel project is so much more than just cannabis. We are currently working to compete the program to prove the viability to deliver drugs through the mucosa with our sol-gel delivery. We are using cannabinoids currently. We don’t want to cheapen the value of this. If we rush to market and sell it as a over the counter drug. We would discount the value that producing a pharmaceutical drug can provide.
However this does not eliminate PreveCeutical from using the sol-gel delivery for other pharmaceutical drug companies to license as a delivery system for their treatments.
Of course there is licensing requirements etc. But that’s things we continue to pursue. "

[marktheinvestor]

Good luck to all![color=red][/color]

@PREV PreveCeutical positive nasal tissue results opens the doors to tremendous possibilities.

— Stephen Van Deventer (@DeventerStephen) January 9, 2020

[marktheinvestor]

PREV IS MENTIONED IN THIS REPORT!

https://www.bccourier.com/2020-brain-cancer-market-report-share-size-and-trend-industry-analysis-report-forecast-to-2024/

[marktheinvestor]

Asterion - Corporate presentation | January 2020
"PreveCeutical will customize to extend their product suite into cannabis product range" Slide 21
" Our partner company, PreveCeutical, will continue to develop novel formats to increase bioavailability and enable managed dosing. " Slide 22
"Proposed products (under license application to ODC*): [...] Cannabis extract/API nasal ‘Sol-Gel’ spray " Slide 23

[marktheinvestor]

Interesting! Another patent filed yesterday for sol-gel composition

LINK

[ZDSinvesting]

Can’t wait!!!

[marktheinvestor]

NEWS!!

https://www.google.ca/amp/s/www.proactiveinvestors.com/companies/amp/news/911387

[marktheinvestor]

CEO has a new twitter account!
https://twitter.com/DeventerStephen

[marktheinvestor]

NEWS!!! PreveCeutical Announces Positive Results Following a Preliminary Safety Evaluation of Sol-Gel Formulations When Applied to Human Nasal Tissue

PreveCeutical Announces Positive Results Following a Preliminary Safety Evaluation of Sol-Gel Formulations When Applied to Human Nasal Tissue

[marktheinvestor]

FTMIG Presents: The Major Milestones Asterion is Celebrating in 2020

__________

ALSO
[JANUARY 2 , 2020]
Asterion Announces $10 Million Private Placement

Vancouver, British Columbia: Asterion Cannabis Inc.(“Asterion” or the “Company”), announces a non-brokered private placement of up to 6,666,667 units (each, a “Unit”) at the price of CAD $1.50 per Unit, for aggregate gross proceeds of up to CAD $10,000,000 (the “Financing”). Each Unit will consist of one common share in the capital of the Company (each, a “Share”) and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”), with each whole Warrant entitling the holder thereof to purchase one additional Share at an exercise price of CAD $2.00 for a period of 24 months from the closing of the Financing, subject to acceleration. Finder’s fees may be payable on a portion of the Financing. All securities issued under the Financing will be subject to a hold period of four months and one day in Canada.

Proceeds from the Financing are intended to be used to construct approximately 40 hectares (99 acres) of cutting-edge, secure, purpose-built greenhouses near Toowoomba in South East Queensland, Australia (the “Toowoomba Facility”) for the production of high-quality organic medicinal cannabis, and for general working capital purposes. For more information on the Toowoomba Facility, see Asterion’s corporate website.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the United States, or in any jurisdiction in which such an offer or sale would be unlawful. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”) or any United States state securities laws, and may not be offered or sold in the United States or to the account or benefit of a “U.S. person” (as defined in Regulation S under the 1933 Act) or a person in the United States absent registration or an applicable exemption from the registration requirements.

[marktheinvestor]

Asterion Awarded Medicinal Cannabis Licences from the Australian Office of Drug Control
_____
Whopping $500m cannabis project receives Federal licences
THE company behind a $500 million medicinal cannabis facility in Toowoomba has overcome its last major regulatory hurdle, receiving its licences from the Federal Office of Drug Control.

Asterion Australia director of communications and business development Dave Holland said the granting of three licences for cultivation of cannabis, research of cannabis and for the manufacturing and processing of the plant into medicines came through late on Friday evening.

The company expects to begin construction at its 75ha site at Wellcamp within the first quarter of next year, with cultivation of its first crop in 2022.

Mr Holland said the company was now in the process of getting ready to build, and was also starting to think about how to train up a workforce of more than 1000 people to work on the site.

“In terms of employment the next phase of us is to engage with trainers and so we’ll be having discussion at least initially with Toowoomba TAFE. We’ve had an introduction to them and are looking to see how we can crank that up,” he said.

“And we need to develop a trained workforce of more than 1000 people, most of whom could start as unskilled workers and go through what we envisage is a Cert II course in advanced horticulture, one designed specifically around the operation.”

Mr Holland said the first stage of production would involve “quite specialised staff” working to cultivate plants in the tissue culture facility, which would begin in the first half of 2022.

“Then it’ll be broader cultivation and processing staff in the next phase,” he said.

“We’re all very positive and excited. We’ve been talking to the contractors we’ve been working with and everyone’s just raring to go now. We’ve got the keys to ignition. It just kicks off now.”

Asterion chairman and CEO Stephen Van Deventer said on completion, the Toowoomba facility was expected to harvest more than 20,000 plants a day, and to generate an estimated $2 billion annually in exports, while also supplying medicinal cannabis to the Australian market.

The facility will consist of four glasshouse “modules”, capable of producing 500 tonnes a year of dried cannabis for medicinal use, as well as processing, packing and tissue culture facility and administration building.

The issuing of the licence also allows the company to move to the next phase of capital raising, with plans to list the company on the Toronto Stock Exchange around March, Mr Holland said.

[JEB1958]

Thanks for the update. Was wondering what was going on. Maybe this will kickstart some action.

[marktheinvestor]

Aurora Exports Dried Cannabis Flower and Oils to Australia for Research by PreveCeutical

Edmonton, AB and Vancouver, BC - March 13, 2018 – Aurora Cannabis Inc. (“Aurora”) (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, Frankfurt: 18H) today announced the grant of three permits by the Australian Government, Department of Health, for the importation of cannabis into Australia for research purposes (the “Permits”). The Permits were granted to the Pharmacy Australia Centre of Excellence (“PACE”) at the University of Queensland (“UQ”) and allow PACE to import shipments of cannabis plant material for research purposes. Aurora, in turn, has received the required Canadian permits to export the cannabis to PACE.

The cannabis will be shipped from Canada by Aurora and used for PreveCeutical’s soluble gel (“Sol-gel”) drug delivery research program (the “Program”), which is being conducted by PreveCeutical’s research partner UniQuest Pty Inc. and led by PreveCeutical’s Chief Research Officer, Dr. Harendra Parekh. The Program aims to develop a system that will increase the bioavailability of drugs by using a nose-to-brain delivery system.
PreveCeutical intends to apply Sol-gel technology to cannabinoids to develop therapies for relief from a range of symptoms, including pain, inflammation, seizures and neurological disorders (see news release dated April 24, 2017). The Permits will enable PreveCeutical to test an array of cannabis strains for the development and commercialisation of cannabinoid-based Sol-gels. The advantages of Sol-gels over conventional liquid nasal sprays relate to longer therapeutic effects, reduced dosage requirements, and reduced irritation and other negative side effects.
In consideration of the shipment, Aurora has received certain rights, including the option to either license, on a non-exclusive basis, the technology for Canada and Australia, or to opt for a royalty arrangement on product sales, as well as to purchase shares in PreveCeutical.
“We see an important market for cannabis-based products that are more narrowly targeted at specific therapeutic areas but that are higher value add and being involved with initiatives such as PreveCeutical’s is part of our strategy to gain access to these types of products,” said Terry Booth, CEO of Aurora.
PreveCeutical’s CEO and Chairman, Mr. Stephen Van Deventer added, “We are extremely excited to receive the Permits, allowing us to further our Sol-gel research program with the high quality cannabis products provided by Aurora. The goal of the Program is to cultivate a range of therapies that will benefit people with ailments such as epilepsy, pain and inflammation, safely and economically.”

[marktheinvestor]

If anyone is wondering what is the link between ASTR & PREV

COPY PAST FROM STOCKHOUSE :
1. Licensing Agreement with Asterion

Under the terms of the Licensing Agreement, Asterion has granted to PreveCeutical a non-exclusive licence (with a right to sublicense in accordance with the terms of this Agreement) to use Asterion’s intellectual property to make or have made, use, distribute, sell, offer to sell and promote the Products for an inital term of five years, renewable for five consecutive one year terms. PreveCeutical will pay to Asterion a royalty equal to 20% of the gross sales from the Products sold by PreveCeutical.

2. PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property
PreveCeutical Medical Inc. (“PreveCeutical”)(CSE: PREV, OTCQB: PRVCF, FSE: 18H), and Asterion Cannabis Inc.(“Asterion”) announce that they have entered into an option to purchase agreement (the “Option Agreement”), whereby PreveCeutical has granted to Asterion the right and option (the “Option”) to purchase up to 51% of PreveCeutical’s right, title and interest in and to certain intellectual property rights relating to a soluble gel (“Sol-Gel”) nasal delivery system for the nose-to-brain delivery of therapeutic formulations, including cannabis and cannabinoids (the “Sol-Gel IP”).

Also, Asterion Cannabis is owned by Stephen Van Deventer, the CEO of Preveceutical.

If people are wondering why PREV sold 51% of the Intellectual Property to Asterion..

Asterion acquired 51 percent of Sol-Gel. The Australian government really likes the Sol-Gel because they would rather see patients take cannabis medicine in pill form, as a gel cap, transdermal or a nasal spray or sublingual tablet rather than smoking cannabis. With Asterion taking the major position of 51 percent ownership, now we can use the major project status to help accelerate that through the process for approvals.

And for those who don't know it yet , Preveceutical has applied for the sol-gel delivery platforms patent on december 5.
2019904601: Sol-gel composition

[marktheinvestor]

Asterion Awarded Medicinal Cannabis Licences from the Australian Office of Drug Control[color=red][/color]

Vancouver, British Columbia--(Newsfile Corp. - December 23, 2019) - Asterion Cannabis Inc. ("Asterion" or the "Company"), announces that its wholly-owned Australian subsidiary ("Asterion Australia") has received its licences for the cultivation, manufacturing and research of medicinal cannabis (the "Licences") from the Australian Government's Office of Drug Control ("ODC"), effective December 20, 2019.

"This is a major milestone for Asterion as it prepares to commence work on its industry leading medicinal cannabis cultivation and processing facility near Toowoomba in South East Queensland, Australia" (the "Toowoomba Facility") stated Mr. Stephen Van Deventer, Asterion's Chairman and Chief Executive Officer. "Asterion is delighted that it has passed through the ODC's rigorous assessment process and been awarded the licences it requires to establish its flagship project. The ODC approvals represent a major step for Asterion towards the manufacturing of pharmaceutical-grade medicinal cannabis at our planned 75 ha (185 acre) Toowoomba Facility."

Stephen Van Deventer, further stated, "Asterion intends to commence work on the Toowoomba Facility in the first quarter of 2020 and is expected to commence cultivation of its first crop in 2022. On completion, the Toowoomba Facility is expected to employ more than 1,000 people harvesting more than 20,000 plants a day, and to generate an estimated AUD $2 billion annually in exports, while also supplying medicinal cannabis to the Australian market. Asterion is committed to its program of innovation across the supply chain, with the goal furthering the development of medicinal cannabis-based pharmaceuticals to provide a safe and effective treatment for a variety of medical conditions."

The Licences authorize Asterion Australia to cultivate cannabis plants and process them into a range of medicinal cannabis products, including natural dried cannabis flower, (across a variety of strains, aimed at specific medical conditions) as well as gel capsules, oils and soluble gels.

About Asterion

Asterion is a Canadian medicinal cannabis company with operations in Australia, specializing in innovation in the development and supply of medical cannabis and is focused on becoming an industry leader in next generation cannabis products. Asterion is focused on the future of advanced agriculture and aims to produce the highest quality of genetically uniform cannabis strains, at an affordable price.

Asterion is led by a team of highly experienced executives with over 120 years of combined experience in medical cannabis, renewable energy, capital markets, and other highly relevant sectors across North America, Oceania, Europe, Africa and Asia.

On Behalf of the Board of Directors

"Stephen Van Deventer"
Chief Executive Officer

For further information, please contact:

Deanna Kress
[phone]
[e-mail]

[Dust2332]

I got out good luck to yall

[Dust2332]

PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property
 

August 6, 2019, Vancouver, British Columbia: PreveCeutical Medical Inc. (“PreveCeutical”)(CSE: PREV, OTCQB: PRVCF, FSE: 18H), and Asterion Cannabis Inc. (“Asterion”) announce that they have entered into an option to purchase agreement (the “Option Agreement”), whereby PreveCeutical has granted to Asterion the right and option (the “Option”) to purchase up to 51% of PreveCeutical’s right, title and interest in and to certain intellectual property rights relating to a soluble gel (“Sol-Gel”) nasal delivery system for the nose-to-brain delivery of therapeutic formulations, including cannabis and cannabinoids (the “Sol-Gel IP”). 
 
PreveCeutical’s President and Chief Science Officer, Dr. Mak Jawadekar stated, “This option agreement presents a unique and timely opportunity for PreveCeutical.  We are excited to further our existing strategic partnership with Asterion and are confident that Asterion will assist PreveCeutical in the rapid commercialisation of the Sol-Gel IP.”
 
Stephen Van Deventer, Asterion’s Chairman and CEO stated, “We are pleased that our partner, PreveCeutical, has granted Asterion the exclusive option to purchase an interest in the innovative Sol-Gel IP, which provides Asterion with the option to acquire intellectual property that compliments its current business.”
 
Commercial Terms

To exercise the Option, Asterion, at discretion, will be required to make a series of cash payments to PreveCeutical in the aggregate amount of $2,652,000 as follows:
 Payment DatePayment Amount (CAD)Earned InterestEffective Date$325,0006.25%July 22, 2019$325,00012.50%(additional 6.25%)August 22, 2019$325,00018.75%(additional 6.25%)September 22, 2019$390,00026.25%(additional 7.50%)October 22, 2019$390,00033.75%(additional 7.50%)November 22, 2019$390,00041.25%(additional 7.50%)December 22, 2019$507,00051.00%(additional 9.75%)TOTAL:$2,652,00051% 
By making all of the above cash payments to PreveCeutical, Asterion will be deemed to have exercised the Option in full; provided that prior to the exercise of the Option in full, Asterion will have, and will be deemed for all purposes to have, acquired the various interests in and to the Sol-Gel IP (each, an “Earned Interest”), upon making the corresponding payment amounts to PreveCeutical as set forth in the above table.  
 
Upon the the earlier of ten days after the date of the exercise by Asterion of the Option in full and December 22, 2019 (the “Participation Date”), PreveCeutical and Asterion will be deemed to have entered into a joint venture for the continued development and commercialization of the Sol-Gel IP (the “Joint Venture”) in which Asterion’s participating interest will be 51% and PreveCeutical’s participating interest will be 49%, assuming that the Option is exercised in full.  On or prior to the Participation Date, the Parties intend to enter into a joint venture agreement (the “Joint Venture Agreement”) that will provide for the ownership, development and commercialization of the Sol-Gel IP.
 
Prior to the Participation Date, PreveCeutical is solely responsible to fund the costs for the continued development and commercialization of the Sol-Gel IP.  After the Participation Date, each of PreveCeutical and Asterion will be required to fund such costs in proportion to its respective participating interest in the Joint Venture, from time to time.
 
The Option is subject to a buy-back right held by PreveCeutical (the “Buy-Back Right”), whereby PreveCeutical will have the right to buy-back all, but not less than all of the Earned Interest by Asterion to such date at any time prior to the Participation Date by paying to Asterion an amount equal to 150% of the aggregate amount of all cash payments made by Asterion to PreveCeutical under the Option Agreement. 
 
The ability of PreveCeutical to transfer up to a 51% interest in the Sol-Gel IP is subject to PreveCeutical having obtained the necessary consents from UniQuest Pty Limited (the “UniQuest Consent”). Pursuant to the Option Agreement, if the UniQuest Consent is not obtained prior to the Participation Date, then PreveCeutical will be deemed to have exercised the Buy-Back Right and either: (i) PreveCeutical will be required to pay Asterion an amount equal to 110% of the aggregate amount of all cash payments made by Asterion to PreveCeutical under the Option Agreement (the “Repayment Amount”) within 10 days of the Participation Date; or (ii) the Repayment Amount will be deemed to be a loan by Asterion to PreveCeutical accruing interest at a rate of 8% per annum, compounding annually, with a maturity date of 24 months after the Participation Date.
 
About PreveCeutical
 
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
 
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; a Sol-Gel drug delivery program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
 
For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticalsand Facebook: www.facebook.com/PreveCeutical.
 
About Asterion 
 
Asterion is a Canadian medicinal cannabis company with operations in Australia, specializing in medical cannabis with a goal of becoming an industry leader in next generation cannabis products. Asterion is focused on the future of advanced agriculture and aims to produce the highest quality genetically uniform cannabis strains, at an affordable price.
 
Asterionis led by a team of highly experienced executives with over 120 years of combined experience in medical cannabis, renewable energy, capital markets, and other highly relevant sectors across North America, Oceania, Europe, Africa and Asia.
 
For more information about Asterion, please visit www.Asterioncannabis.com. 
 On Behalf of the Board of Directors of PreveCeutical 
 
“Dr. Mak Jawadekar”
President and Chief Science Officer
  On Behalf of the Board of Directors of Asterion
 
“Stephen Van Deventer”
Chief Executive OfficerFor further information, please contact:PreveCeutical:
 
Deanna Kress

Director of Corporate Communications &
Investor Relations

[phone]
[e-mail]:
 
 
Investor Relations
[e-mail]

[Dust2332]

https://ca.proactiveinvestors.com/companies/news/224943/asterion-cannabis--queensland-project-gets-big-boost-after-government-ruling-224943.html

[Dust2332]

PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System
 

July 9, 2019, Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that it has completed the second phase of its soluble gel (“Sol-gel”) drug delivery research and development program (the “Sol-gel Program”), by successfully developing formulations for cannabis extract-infused Sol-gels (the “CBD Sol-gel Formulations”), where both the acid and neutral cannabis extract forms have been incorporated.  The resultant wholly-water based CBD Sol-gel Formulations were developed using US-FDA approved excipients and can be complemented by using the Company’s custom Sol-gel applicator device (the “Sol-gel Applicator”) for direct nose-to-brain delivery.
 
PreveCeutical’s research team previously optimized the conditions for comprehensive conversion of phytocannabinoids extracted from the Company’s five cannabis strains from their acid forms to their neutral forms (the “Neutralization Protocol”; see news release dated November 20, 2018), which may open the door to an extensive product range for PreveCeutical.  Accommodating both acid and neutral extracts in the Sol-gels is an important development from a clinical perspective, as reports continue to highlight the respective benefits of acid and neutral extracts in treating a range of diseases and ailments.
 
Having now successfully completed the second phase, the third and final stage of the Sol-gel Program is currently underway. The third phase is expected to assess and profile cannabinoid release from the extract infused Sol-gels, as well as the cannabinoid’s deposition into freshly explanted human nasal mucosal tissue (ex vivo), alongside toxicity evaluation.
 
PreveCeutical’s President and Chief Science Officer, Dr. Mak Jawadekar stated, “It will be exciting to see how these ongoing ex-vivo studies conducted using human explanted tissues may help us get an early read out on our proprietary drug delivery applicator device for the targeted central nervous system delivery of cannabinoids.”
 
The CBD Sol-gel Formulations, when used with the Company’s customized Sol-gel Applicator, are expected to allow for the direct and prolonged delivery of cannabinoids to a patients’ central nervous system (CNS).  Future studies, outside of the current Sol-gel Program may involve pre-clinical/clinical evaluation of the CBD Sol-gel Formulations as the Company’s medicinal cannabis division hopes to be able to offer a broad product range of formulations that can be tailored to specific medical conditions.

[thegameison13524]

More news to come. Hope it’s not quite so technical

[Dust2332]

PreveCeutical Announces Further Positive Results from its
Dual Gene Therapy Research Program
 

June 17, 2019, Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), is pleased to provide positive results from research conducted for its dual gene therapy research program (the “Program”).  
 
PreveCeutical previously identified four or more novel siRNA constructs, each of which preferentially targeted the gene of interest while reducing the gene’s expression by no less than 80% compared to a random siRNA (control) sequence (see news release dated January 14, 2019). 
 
The siRNA constructs represent the “therapeutic” component of the proposed gene therapy and are an important part of the gene therapy approach for potential application in type 2 diabetes and obesity. PreveCeutical’s research team has now identified and finalised a panel of highly potent and novel siRNA-candidates, each of which significantly (≥50%) silence the target gene and protein in mice and human-derived cells of interest. The lead siRNA sequences comprise those directed to the human variant of PTP-1B, and distinct sequences directed towards the mouse variant of PTP-1B. Synthetic efforts will now focus on introducing proprietary chemistries that enhance the biostability and thermostability of the novel siRNA sequences to generate modified siRNA sequences (“Smart-siRNAs”). Once the first series of Smart-siRNA’s are successfully developed, they are expected to be re-screened in cell-based assays to re-affirm their potency.  This is anticipated to pave the way for evaluation in planned rodent models of disease, which would constitute the final phase of the Program.
 
PreveCeutical’s President and Chief Science Officer, Dr. Mak Jawadekar stated, “We are pleased with the progress being made given that these novel, potent siRNA constructs constitute the most crucial part of the gene therapy approach. This is a positive step in the right direction for the pursuit of our goal to achieve a successful dual gene therapy program.”

[thegameison13524]

Anyone like rumours ? GW pharma interested in solgel technology

[Dust2332]

PreveCeutical Secures $300,000 Loan and Resignation of a Director

FOR IMMEDIATE RELEASE - Vancouver, British Columbia: PreveCeuticalMedical Inc.(the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H) announces that it has received a loan in the aggregate amount of $300,000 (the “Loan”) pursuant to a loan agreement with the Company’s Chairman and Chief Executive Officer, Mr. Stephen Van Deventer (the “Lender”).

Loan Details

The Loan has a one-year term and will bear interest at a rate of 5% per annum, compounded semi-annually and payable on the maturity date.  Pursuant to the Loan, the Company has also granted 5,000,000 transferable bonus common share purchase warrants (each, a “Bonus Warrant”) to the Lender.  Each Bonus Warrant will entitle the holder to purchase one common share in the capital of the Company at an exercise price of $0.06 per share for a period of one year from the grant date. All securities issued pursuant to the Loan will be subject to a hold period of four months and one day in Canada from the date of issuance.  The funds received by the Company from the Loan will be used for general working capital purposes.

As the Lender is a current director and executive officer of the Company, the Loan constituted a related party transaction pursuant to Multilateral Instrument 61 101 - Protection of Minority Security Holders in Special Transactions(“MI 61-101”).  The Company relied on Sections 5.5(a) and 5.7(1)(a) of MI 61-101 for an exemption from the formal valuation and minority shareholder approval requirements, respectively, of MI 61-101, as, at the time the Loan was made available to the Company, neither the fair market value of the subject matter of, nor the fair market value of the consideration for the Loan exceeded 25% of the Company’s market capitalization.

Resignation of a Director

Mr. Greg Reid has stepped down as a director of the Company, effective May 31 2019, to allow for more time to focus on his film making career and Keynote Speaker commitments.

PreveCeutical’s President and Chief Science Officer, Dr. Mak Jawadekar stated, “Greg has served on the PreveCeutical board of directors since the company went public in 2017. He has made many contributions to the success and growth of the company, drawing on his wealth of experience and contacts from his successful business career. On behalf of the board of directors, the management team and our shareholders, I thank Greg and wish him all the best in the future.”

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

[thegameison13524]

What does this penny stock have that merck or fizer or gw pharm or any other big pharma wants? Scorpion venon?

[thegameison13524]

That's good to know. But at 5 cents it doesn't matter.

[Mr.Green]

PRVCF is a OTCQB not a Pink

[Mr.Green]

PRVCF has acquired the human tissue and is now testing, as I understand once that is completed and all is good the next step is FDA approval.

Is this the case?

All sounds great with exciting possibilities.

[thegameison13524]

So why would a $180/share co be interested in this pinker?